Medimmune Limited

Matthieu Chodorge

Ian Nevin Foltz

Jaspal Singh Kang

Scott A Hammond

Michelle Morrow

Melanie Boyle

Laura Sekirov

Marat Alimzhanov

Christophe Queva

Kathleen Ann Mulgrew

Andrew Grier Buchanan

Ross Anthony Stewart

John Babcock

Peter Cariuk

Johanna Husmark

Clare Balendran

Deepesh Pandey

Fumin Chang

Daniel E Berkowitz

Lewis H Romer

John Stephen Babcook

David Fairman

Jonathan Seaman

Peter Ravn

Anthony Celeste

Cristina Rondinone

Joseph Grimsby

Ross A Steward

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

This application provides anti-PCSK9&#x2dc;GLP-1 fusions and methods for use.

Anti-PCSK9-GLP-1 fusions and methods for use

Growing community of inventors

Cambridge, United Kingdom

Matthieu Chodorge